Human umbilical cord cells for cardiovascular tissue engineering: a comparative study

Kadner, Alexander; Zünd, Gregor; Maurus, Christine; Breymann, Christian; Yakarisik, Sidika; Kadner, Gregor; Turina, Marko; Hoerstrup, Simon P.

doi:10.1016/j.ejcts.2003.12.038

Cited by 98 publications

(57 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…UCM cells demonstrate excellent cell growth properties on bioabsorbable polymer constructs (75). UCM cells were used to seed blood vessel conduits fashioned from rapidly bioabsorbable polymers and grown in vitro in a pulse duplicator bioreactor (76).…”

Section: Ucm Cells For Tissue Engineeringmentioning

confidence: 99%

Stem cells in the umbilical cord

2006

View full text Add to dashboard Cite

Stem cells are the next frontier in medicine. Stem cells are thought to have great therapeutic and biotechnological potential. This will not only to replace damaged or dysfunctional cells, but also rescue them and/or deliver therapeutic proteins after they have been engineered to do so. Currently, ethical and scientific issues surround both embryonic and fetal stem cells and hinder their widespread implementation. In contrast, stem cells recovered postnatally from the umbilical cord, including the umbilical cord blood cells, amnion/placenta, umbilical cord vein, or umbilical cord matrix cells, are a readily available and inexpensive source of cells that are capable of forming many different cell types (i.e., they are "multipotent"). This review will focus on the umbilical cord-derived stem cells and compare those cells with adult bone marrow-derived mesenchymal stem cells.

show abstract

Section: Ucm Cells For Tissue Engineeringmentioning

confidence: 99%

Stem cells in the umbilical cord

2006

View full text Add to dashboard Cite

show abstract

“…Thus, Naughton et al [33] and Purchio et al [34] derived "prechondrocytes," from explant cultures of UC WJ, and Mitchell et al [35], using a similar approach, reported that the fibroblast-like cells of WJ could be induced to differentiate into "neural-like" cells expressing neuron-specific enolase (NSE), as well as other neural cell markers. Romanov et al [36], using a different approach, enzymatically digested mesenchymal precursor cells from the UC vasculature endothelial surface, and Kadner et al [37,38] minced either UC vessels or whole cord to derive an autologous cell source of myofibroblasts for cardiovascular tissue engineering. Chacko and Reynolds [39] described the cells residing in WJ as "smooth muscle cells," but Takechi et al [40] refined the description to "myofibroblasts" after in situ labeling of vimentin, desmin, α-actin, and myosin, which has been recently confirmed by Kadner et al [38].…”

Section: Introductionmentioning

confidence: 99%

Human Umbilical Cord Perivascular (HUCPV) Cells: A Source of Mesenchymal Progenitors

et al. 2005

View full text Add to dashboard Cite

We describe the isolation of a nonhematopoietic (CD45 -, CD34 -, SH2 + , SH3 + , Thy-1 + , CD44 + ) human umbilical cord perivascular (HUCPV) cell population. Each HUCPV cell harvest (2-5 × 10 6 , depending on the length of cord available) gave rise to a morphologically homogeneous fibroblastic cell population, which expressed α-actin, desmin, vimentin, and 3G5 (a pericyte marker) in culture. We determined the colony-forming unit-fibroblast (CFU-F) frequency of primary HUCPV cells to be 1:333 and the doubling time, which was 60 hours at passage 0 (P0), decreased to 20 hours at P2. This resulted in a significant cell expansion, producing over 10 10 HUCPV cells within 30 days of culture. Furthermore, HUCPV cells cultured in nonosteogenic conditions contained a subpopulation that exhibited a functional osteogenic phenotype and elaborated bone nodules. The frequency of this CFU-osteogenic subpopulation at P1 was 2.6/10 5 CFU-F, which increased to 7.5/10 5 CFU-F at P2. Addition of osteogenic supplements to the culture medium resulted in these frequencies increasing to 1.2/10 4 and 1.3/10 4 CFU-F, respectively, for P1 and P2. CFU-O were not seen at P0 in either osteogenic or non-osteogenic culture conditions, but P0 HUCPV cells did contain a 20% subpopulation that presented neither class I nor class II cell-surface major histocompatibility complexes (MHC -/-). This population increased to 95% following passage and cryopreservation (P5). We conclude that, due to their rapid doubling time, high frequencies of CFU-F and CFU-O, and high MHC -/-phenotype, HUCPV cells represent a significant source of cells for allogeneic mesenchymal cell-based therapies. Stem Cells 2005;23:220-229

show abstract

“…Although hUC-MSCs have exhibited a therapeutic effect in DMD/BMD, MSCs derived from different tissue sources have not been uniformly effective in clinical practice (23). MSCs derived from the umbilical cord have a significant advantage over those derived from bone marrow, placenta, or other tissues, as hUC-MSCs are easy to acquire and culture, and the cells have a high proliferation rate (32) and low immunogenicity (33).…”

Section: Discussionmentioning

confidence: 99%

“…Cells isolated from the umbilical cord tissue have also been shown to be more effective in rescuing photoreceptors and visual function, and to be capable of sustained population doublings without karyotypic changes, thus proving useful in retinal diseases (21). Cultured mesenchymal stem cells (MSCs) from the human umbilical cord artery (UCA), umbilical cord vein (UCV), whole umbilical cord (UCC) and saphenous vein segments have exhibited a myofibroblast-like morphology and mechanical function in vitro (23). The cells are abundant, easy to harvest and to culture and have lower immunogenicity.…”

Section: Introductionmentioning

confidence: 99%

Transplantation of human umbilical cord-derived mesenchymal stems cells for the treatment of Becker muscular dystrophy in affected pedigree members

Pang

Cui

Zhang

et al. 2015

International Journal of Molecular Medicine

View full text Add to dashboard Cite

Abstract. The regeneration of muscle tissue has been achieved using multipotent mesenchymal stem cells in mouse models of injured skeletal muscle. In the present study, the utility of multipotent human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) in the treatment of Becker muscular dystrophy (BMD), a genetic disease where muscle tissue fails to regenerate, was examined in members from a pedigree affected by BMD. The disease status was evaluated in 4 affected pedigree members (II1, II2, II3 and III2; aged 50, 46, 42 and 6 years, respectively). The transplantation of the hUC-MSCs (performed on 3 patients, I2, II3 and III2) was performed by infusion with an intravenous drip over a 30-min period, and the patients were evaluated at 1, 3, 4 and 12 weeks following the procedure. The evaluation was based on physical characteristics, as well as on molecular testing for serum creatine kinase (CK) and lactate dehydrogenase (LDH) levels and a histological examination of muscle biopsies. The patients suffered no adverse reactions in response to the transplantation of the hUC-MSCs. At 1 week following transplantation all 3 patients showed improvement in the muscle force of the limbs, muscle size and daily activity. The walking gait of patient III2 had improved by 1 week post-transplantation and reached a normal status by 12 weeks. Serum CK and LDH levels were decreased relative to the baseline levels. A histological examination of muscle biopsies displayed no obvious tissue regeneration. In conclusion, the treatment of patients with BMD using hUC-MSCs was safe and of therapeutic benefit that lasted for up to 12 weeks. hUC-MSCs are, therefore, a potential cell therapy-based treatment option for patients with muscular dystrophies.

show abstract

Human umbilical cord cells for cardiovascular tissue engineering: a comparative study

Cited by 98 publications

References 17 publications

Stem cells in the umbilical cord

Stem cells in the umbilical cord

Human Umbilical Cord Perivascular (HUCPV) Cells: A Source of Mesenchymal Progenitors

Transplantation of human umbilical cord-derived mesenchymal stems cells for the treatment of Becker muscular dystrophy in affected pedigree members

Contact Info

Product

Resources

About